Promoting the Supply of Memopatch M and Other Solutions to U.S. Hospitals

On March 30, Yuhan Corporation announced that its U.S. subsidiary, Yuhan USA, and the digital healthcare innovation company Huino have signed a strategic business agreement to penetrate the U.S. digital healthcare market.


The agreement focuses on facilitating the entry and expanding the market share in the U.S. for Huino's AI-powered electrocardiogram (ECG) monitoring solution lineup (Memopatch M, MemoQ, and MemoCare) as well as its clinical prediction solution, "Vital Picasso." Under this agreement, the two companies plan to closely collaborate on various business aspects, including: establishing sales channels in the U.S., developing local marketing and brand strategies, responding to regulatory and approval processes, supporting logistics and operations, and identifying new business opportunities.

Taewon Yoon, CEO of Yuhan USA (left), and Youngjoong Gil, CEO of Huino, are taking a commemorative photo at the business agreement ceremony for Huino's entry into the U.S. market on the 26th. Yuhan Corporation

Taewon Yoon, CEO of Yuhan USA (left), and Youngjoong Gil, CEO of Huino, are taking a commemorative photo at the business agreement ceremony for Huino's entry into the U.S. market on the 26th. Yuhan Corporation

View original image

Memopatch M is an ultra-lightweight wearable ECG device capable of continuous monitoring for up to eight days. MemoQ, which includes Memopatch M, is a smart AI telemetry solution that analyzes inpatients' ECG data in real time, enables early detection of abnormalities, and supports prompt decision-making by medical professionals. MemoCare is a long-term ECG analysis solution that uses AI to analyze ECG data collected for up to 14 days.


Vital Picasso, developed in-house by Huino's subsidiary HuinoAim, is a solution that analyzes vital sign data from general ward patients to predict major clinical deteriorations such as hypotension, hypoxemia, and cardiac arrest in advance. Last year, it was designated as an innovative medical device by the Ministry of Food and Drug Safety.



A Yuhan Corporation representative stated, "Through this joint entry into the U.S. market, made possible by the agreement between the two companies, we expect that Memopatch M, MemoQ, and other solutions in the field of ECG monitoring and clinical prediction will help medical staff make rapid decisions and enhance the efficiency of patient management in both intensive care units and general wards."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing